BackgroundSurgery is a cornerstone in the treatment of esophageal cancer, yet high postoperative recurrence rates remain a significant challenge. This study aimed to retrospectively examine the trends in postoperative recurrence rates of esophageal cancer over the past decade and identify factors influencing these trends.MethodsData from 918 esophageal cancer patients who underwent surgery at Jining First People’s Hospital between January 2013 and May 2021 were analyzed. The follow-up period ranged from 32 to 98 months. Monthly recurrence rates were calculated to observe trends over time. Surgical techniques included various open and minimally invasive approaches. Follow-up assessments involved regular clinical evaluations and imaging studies. Statistical analyses were performed using SPSS, GraphPad Prism, and R software to identify factors influencing recurrence.ResultsA total of 918 patients were included, with 224 experiencing local recurrence. The local recurrence rate showed a significant year-over-year decline (p = 0.000), primarily driven by a reduction in upper mediastinal lymph node recurrence (r = 0.4086, p = 0.0006). In contrast, distant recurrence rates did not exhibit a significant trend. Univariate and multivariate analyses identified several factors influencing upper mediastinal lymph node recurrence, including surgical method, alcohol consumption, number of lymph nodes dissected, and pTNM stage. Minimally invasive esophagectomy (MIE) was found to be an independent factor associated with a reduced monthly recurrence rate in the upper mediastinum (r = -0.3009, p = 0.0134).ConclusionsThe study demonstrated a consistent decline in local recurrence rates over the past decade, particularly in upper mediastinal lymph nodes. The adoption of minimally invasive surgical techniques, improvements in perioperative management, and the evolving role of neoadjuvant therapy likely contributed to this trend.

Background:The study was conducted in order to investigate whether neoadjuvant immunotherapy combined with chemotherapy can bring survival benefits to patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC) in the real world. Methods:We retrospectively analysed patients with locally advanced resectable ESCC who underwent surgery at the Jining First People's Hospital from April 2020 to April 2022. Based on their medical history, the enrolled patients were divided into a neoadjuvant immunochemotherapy plus surgery group (nICT group) and a surgery-only group (S group). Primary endpoints were the two-year overall survival (OS) and disease-free survival (DFS) rates. Secondary endpoints were the safety and efficacy of neoadjuvant immunochemotherapy for patients with locally advanced esophageal cancer, and compared the surgery and postoperative outcomes between the two groups. Results:A total of 47 patients in the nICT group and 73 patients in the S group were included for further analysis, the stage of the nICT group was more advanced than that of the S group. In the group nICT, 8 patients (17%) achieved the complete pathological response (pCR), 29 patients (61.7%) achieved major pathological response (MPR), including 6 patients (12.8%) with a primary tumor achieving pCR but had residual tumor cells in the lymph nodes (pT0N+), and the treatment-related AES was manageable. The surgery and postoperative outcomes were comparable in both groups. The two-year OS and DFS rates for the nICT group were 91.5% and 85.5% respectively, while those for the S group were 71.2% and 68.5%, and Kaplan-Meier survival analysis and log-rank test revealed significant differences in DFS and OS between the two groups. Patients who achieved MPR in the nICT group showed better DFS and OS, while the Three-cycle subgroup did not exhibit any survival benefit compared to the Two-cycle subgroup. Conclusions:Neoadjuvant sintilimab combined with chemotherapy has promising efficacy and safety in the treatment of locally advanced resectable ESCC. The treatment modality has the potential to become a standard therapy for locally advanced resectable ESCC.

To explore whether neoadjuvant Sintilimab is suitable for patients with gastroesophageal junction (GEJ) adenocarcinoma, we designed this study to evaluate the short-term efficacy and safety of neoadjuvant Sintilimab in combination with chemotherapy for resectable GEJ adenocarcinoma. We retrospectively collected data on patients with GEJ adenocarcinoma who underwent surgery after receiving neoadjuvant immunotherapy combined with chemotherapy at Jining First People’s Hospital between October 2020 and October 2023. The primary endpoint was complete pathological response (pCR) rate; secondary endpoints: major pathological response (MPR) rate, neoadjuvant therapy-related adverse events (AES), the safety of surgery, Postoperative Complications, and overall survival (OS). 24 eligible patients were enrolled in the study and achieved a pCR rate of 16.7

Breast cancer and lung cancer are the two most common malignancies in China. With the continuous improvement of breast cancer diagnosis and treatment technology, the survival time of breast cancer patients has been prolonged, and the number of breast cancer patients with second primary lung cancer (SPLC) has increased. In addition, breast cancer is the most common primary cancer in female patients with SPLC, and SPLC is the main cause of death in this population. More and more physicians pay attention to this clinical phenomenon. This paper summarized the risk and risk factors of SPLC in breast cancer patients, and elaborated its pathogenesis, in order to provide a theoretical basis for the clinical management of breast cancer patients and achieve accurate early intervention as soon as possible.
.

Worldwide, lung cancer is the leading cause of death among malignancies.Early diagnosis of malignant pulmonary nodules is the key of lung cancer prevention, therefore, it is necessary to search an effective screening method for early diagnosis.The spread of CT screening has reduced the mortality of lung cancer, but it has also brought new challenges to the workload, sensitivity and accuracy of imaging diagnosis.In recent years, artificial intelligence has made significant progress in the assessment of pulmonary nodules, among which, deep learning-based artificial intelligence is a rapidly developing technology that is considered a beneficial tool for the detection, characterization and assessment of lesions in the field of medical image analysis.This paper reviews the recent progress of deep learning in the detection and diagnosis of lung nodules through CT scanning, and also identify such limitations and challenges and outline solutions, aiming to improve clinicians′ understanding of deep learning-based artificial intelligence in the diagnosis of pulmonary nodules.

目的 探讨人工智能(artificial intelligence,AI)影像诊断系统和CT血管支气管三维重建(three dimensional computed tomographic bronchoangiography,3D-CTBA)手术规划系统在多原发肺癌(multiple primary lung cancer,MPLC)诊治中的应用价值.方法 回顾性分析2018年1月至2020年8月于我院行手术治疗的53例MPLC患者的临床资料,其中男16例、女性37例,中位年龄60 (39～75)岁.分别采用AI和人工分析患者术前CT.整理行3D-CTBA患者资料,评价AI和3D-CTBA在MPLC诊治中的应用价值.结果 AI筛查MPLC的敏感性为84.91％.AI识别MPLC高危浸润性病变的敏感性(91.90％ vs.83.78％)、准确性(85.60％ vs.84.00％)不弱于人工判读.12例患者应用3D-CTBA进行术前规划,术中情况与重建结果基本相符.结论 AI在识别MPLC浸润性病变中具有辅助诊断价值.3D-CTBA重建解剖结构准确,可指导术前规划.